Drug Trial Radar · NCT01777269
Prospective Sexual Function Study for BPH Subjects
Last checked: Nov 20, 2026Latest source record: Aug 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
489
Actual
Start
Feb 18, 2013
Primary completion
Apr 5, 2016
Study completion Apr 5, 2016
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 28, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an European double-blind, placebo controlled parallel group comparison of DUODART (fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg, one capsule daily) and placebo. PRIMARY OBJECTIVE: To assess the change in sexual function from baseline to 1 year in sexually active men with at least moderate BPH who are treated with DUODART, compared to men treated with placebo .
Conditions
- Prostatic Hyperplasia
Interventions
Dutasteride plus tamsulosinDrug
Take 1 capsule daily
PlaceboDrug
Take one capsule daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes From Baseline (BL) in Total Score From the Full Men's Sexual Health Questionnaire (MSHQ) at 12 MonthsTime frame: Baseline and 12 months
Locations
67 sites in 7 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Randwick, New South Wales, Australia
GSK Investigational Site
Sydney, New South Wales, Australia
GSK Investigational Site
Wahroonga, New South Wales, Australia
GSK Investigational Site
Herston, Queensland, Australia
GSK Investigational Site
Kippa-Ring, Queensland, Australia
GSK Investigational Site
Adelaide, South Australia, Australia
GSK Investigational Site
Heidelberg, Victoria, Australia
GSK Investigational Site
Malvern, Victoria, Australia
GSK Investigational Site
Garches, France
GSK Investigational Site
Nantes, France
GSK Investigational Site
Nîmes, France
GSK Investigational Site
Orléans, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Thouars, France
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Eisleben Lutherstadt, Germany
GSK Investigational Site
Nuremberg, Bavaria, Germany
GSK Investigational Site
Hagenow, Brandenburg, Germany
GSK Investigational Site
Oranienburg, Brandenburg, Germany
GSK Investigational Site
Strausberg, Brandenburg, Germany
GSK Investigational Site
Marburg, Hesse, Germany
GSK Investigational Site
Buchholz, Lower Saxony, Germany
GSK Investigational Site
Aachen, North Rhine-Westphalia, Germany
GSK Investigational Site
Dortmund, North Rhine-Westphalia, Germany
GSK Investigational Site
Dülmen, North Rhine-Westphalia, Germany
GSK Investigational Site
Leipzig, Saxony, Germany
GSK Investigational Site
Hettstedt, Saxony-Anhalt, Germany
GSK Investigational Site
Kiel, Schleswig-Holstein, Germany
GSK Investigational Site
Wedel, Schleswig-Holstein, Germany
GSK Investigational Site
Argos, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Larissa, Greece
GSK Investigational Site
Budapest, Hungary
GSK Investigational Site
Budapest, Hungary
GSK Investigational Site
Budapest, Hungary
GSK Investigational Site
Debrecen, Hungary
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.